ACR 2016 Preview: Biosimilars On Par with Originators yet Patients Remain Skeptic

Nov 03, 2016

In this slideshow, we preview biosimilar studies due to be presented at the American College of Rheumatology annual meeting Nov. 11-16 in Washington, D.C.

Biosimilars are becoming more common for patient treatments, and the body of data around their safety and efficacy continues to grow. Patient satisfaction has also been a frequent study topic. In this slideshow, we highlight some studies that examine biosimilar use compared to originator products. These studies, and more, will be presented during the American College of Rheumatology 2016 annual meeting, Nov. 11-16 in Washington, D.C.

(Â©Zonda/Shutterstock.com)

James Piercy, et. al. “Patient Attitude Towards Being Prescribed Biosimilars in Inflammatory Autoimmune Diseases in Germany,” 2016 ACR/AHRP Annual Meeting. Abstract Number: 1428

Robert Moots, et. al. “Switching to Biosimilars in Rheumatology Evidence-Based Practice,” 2016 ACR/AHRP Annual Meeting. Abstract Number: 639

Tore K. Kvien, Guro Lovik Goll, et. al., “Biosimilar Infliximab (CT-P13) Is Not Inferior to Originator Infliximab: Results From a 52-Week Randomized Switch Trial in Norway,” 2016 ACR/ARHP Annual Meeting. Abstract Number: 19L